Polynucleotides Injectable Market Size, Share & Trends Analysis Report By Application (Eyes, Lips, Forehead, Jawline & Cheekbones), By End-use (MedSpas, Aesthetic & Cosmetic Centers), By Region, and Segment Forecasts, 2024 - 2030

Polynucleotides Injectable Market Trends

The global polynucleotides injectable market size was estimated at USD 111.5 million in 2023 and is projected to grow at a CAGR of 14.9% from 2024 to 2030.Technological advancements in biotechnology primarily drive the market, as do the growing demand for skin rejuvenation, personalized medicine, and investments in research and development (R&D). According to an article published by PMTA Journal in March 2024, polynucleotide injections gained prominence in aesthetic medicine due to their beneficial effects on skin, hair, and other tissues, as explored in this comprehensive review.

The growing demand for advanced skin rejuvenation treatments is a primary driver of the polynucleotides injectable market. As individuals seek more effective solutions to address signs of aging, such as fine lines, wrinkles, and skin laxity, the interest in novel injectable treatments such as polynucleotides has surged. For instance, a recent study published in the journal Dermatologic Therapy found that polynucleotide injections improved skin tone, fine lines, skin elasticity, and hydration in patients in their 30s and 40s.

The increasing focus on personalized medicine also contributed to the growth of the market. As healthcare providers and patients alike seek customized approaches to skin rejuvenation, polynucleotides' ability to stimulate the body's natural collagen production and cellular regeneration made them a popular choice. This trend is particularly evident in the rising demand for personalized aesthetic treatments, which is expected to continue expanding the market.

Finally, integrating innovative technologies, such as digital imaging and automated injection systems, has further propelled the polynucleotides injectables market. These advancements improved polynucleotide injections' precision, consistency, and safety, making them more appealing to healthcare providers and patients. As the aesthetic industry continues to evolve, incorporating cutting-edge technologies is expected to remain a vital driver of the polynucleotide injectable market. For instance, in 2022, Pulse Light Clinic in London is introducing PhilArt by Croma, an innovative polynucleotide injection treatment recognized for significantly enhancing skin hydration, boosting elasticity, and stimulating natural collagen production - a pioneering advancement in skin rejuvenation.

Application Insights

The eye segment held the largest revenue share of 63.9% in the polynucleotide injectable market, driven by the growing demand for non-invasive solutions to address various eye-related concerns. Polynucleotide injectable improve the appearance of fine lines, wrinkles, and skin laxity around the delicate eye area, which is often a key concern for aging individuals. For instance, a study published in the Journal of Cosmetic Dermatology found that polynucleotide injections significantly improved periorbital skin quality, including increased elasticity and reduced appearance of crow's feet, without the need for more invasive procedures. 

The forehead segment is the fastest growing under the polynucleotide injectable market application segment. The market is driven by the rising consumer preference for minimally invasive aesthetic treatments that can address the visible signs of aging and enhance overall facial aesthetics. For instance, a recent study published in the Journal of Cosmetic Dermatology found that patients who received polynucleotide injections in the forehead area experienced a significant improvement in skin texture, reduced appearance of wrinkles, and enhanced facial rejuvenation without the need for more invasive procedures, include neurotoxins or dermal fillers. 

End-use Insights

The MedSpas segment held the largest revenue share of 50.1% in the polynucleotide injectable market, driven by consumers' growing demand for non-invasive aesthetic treatments. Polynucleotides' unique properties, which enable them to stimulate collagen production, enhance skin texture, and diminish the appearance of fine lines and wrinkles, have made these injectable treatments a highly sought-after option among MedSpa clients seeking natural and long-lasting aesthetic improvements. For instance, an American Med Spa Association survey found 8,841 medical spas operating in the U.S. in 2022 as consumers increasingly sought these facilities to receive treatments such as polynucleotide injections.

The Aesthetic & Cosmetic Centers segment is expected to grow at a significant rate within the polynucleotide injectable market end-use segment. This rapid growth is driven by the rising consumer demand for minimally invasive aesthetic treatments that deliver natural-looking, long-lasting results. Aesthetic & Cosmetic Centers offer a wide range of services, including polynucleotide injectables, which are gaining popularity for improving skin texture, elasticity, and overall appearance. For instance, Pulse Light Clinic stated that polynucleotide injections deeply hydrate the skin, improving elasticity and youthful appearance. They stimulate natural collagen production for long-lasting skin health.

Regional Insights

The polynucleotides injectable market in North America has been experiencing significant growth in recent years, due to increasing demand for advanced therapies and the presence of essential players in the region. The market is primarily driven by advancements in gene therapy and RNA-based therapeutics, as well as the launch of innovative products. Critically, polynucleotide based injectables haven’t received approval from the FDA, thereby, it is expected that the market growth and share of the region will remain at the lower end during the forecast period.

U.S. Polynucleotides Injectable Market Trends

The U.S. polynucleotide injectable market is highly dynamic. It is projected to grow substantially due to the increasing adoption of personalized medicines and the growing demand for targeted therapies. The U.S. has a well-established biopharmaceutical industry, with several companies investing heavily in research and development activities related to polynucleotide-based therapies. The increasing geriatric population, which is more susceptible to skin aging and skin conditions, is also a significant factor driving the demand for effective aesthetic solutions. However, low confidence in the product from doctors & practitioners is expected to hinder growth.

According to a leading dermatologist in the U.S., “I don't know when the FDA is going to ever approve milt-derived chemical compounds for human use in Americans. I would not consider using polynucleotides until I see more long-term safety and outcome data.”

Europe Polynucleotides Injectable Market Trends

The European polynucleotide injectable market is also experiencing significant growth due to an increasing patient population base, easier regulatory approvals, and diverse needs from medical tourists. For instance, more than 140 injectables are approved in Europe as against 22 in the U.S. Furthermore, novel technology penetration for aesthetic intervention is critically higher in the country, which drives growth. Some of the key brands available in the region are Nucleofill, Pluryal Silk, Rejuran, and among others.

Asia Pacific Polynucleotides Injectable Market Trends

The Asia Pacific polynucleotide injectable market held the largest revenue share of 50.5% in 2023 as the region is witnessing several key trends, including the emergence of domestic players offering low-cost products to expand market access and affordability. There is a strong presence of domestic competitors and multinational corporations in the region, with domestic players gaining success by catering to country-specific preferences. Innovations and improvements to treatments and products entering the Asia Pacific market also support sales growth, such as the recent approval of novel polynucleotide injectable products.

Key Polynucleotides Injectable Company Insights

Companies employ various strategies to enhance their market share, such as new product launches and partnerships. The growing demand for minimally invasive aesthetic treatments, the rising prevalence of skin conditions, and the increasing focus on personal well-being are the key drivers propelling the growth of the polynucleotide injectable market.

Recent Developments

• In May 2024, PharmaResearch revealed Rejuran's technological innovations in the Vietnamese market. Through this product launch, the company aims to expand its presence in the Vietnamese aesthetic and strengthen Rejuran's position as a global provider of innovative aesthetic solutions.

• In October 2023, LG Chem and BR Pharm signed an MOU to collaborate on developing and approving, HP Vitaran, a skin booster comprising polynucleotide (PN) derived from salmon and other fish reproductive cells, for the Chinese market. This partnership strives to leverage LG Chem's expertise and BR Pharm's regenerative medicine technology.

Polynucleotides Injectable Market Report Scope

Global Polynucleotides Injectable Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global polynucleotides injectable market report based on application, end-use, and region.

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Eyes

  • Lips

  • Forehead

  • Jawline & Cheekbones

  • Others

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • MedSpas

  • Aesthetic & Cosmetic Centers

  • Hospitals

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait